NEPH

Nephros Inc.

3.93

USD

NEPH Earnings Reports

Positive Surprise Ratio

NEPH beat 15 of 26 last estimates.

58%

Next Report

Date of Next Report

Mar 05, 2026

Estimate for Q4 25 (Revenue/ EPS)

$4.54M

$0.01

Implied change from Q3 25 (Revenue/ EPS)

-4.70%

-66.67%

Implied change from Q4 24 (Revenue/ EPS)

+17.31%

-66.67%

Nephros Inc. earnings per share and revenue

On Nov 06, 2025, NEPH reported earnings of 0.03 USD per share (EPS) for Q3 25, beating the estimate of -0.02 USD, resulting in a 247.06% surprise. Revenue reached 4.76 million, compared to an expected 3.94 million, with a 20.80% difference. The market reacted with a -11.54% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 4 analysts forecast an EPS of 0.01 USD, with revenue projected to reach 4.54 million USD, implying an decrease of -66.67% EPS, and decrease of -4.70% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Stryker Corporation

Report Date

Jan 29, 2026 For Q4 25

Estimate

$4.43

Actual

$4.47

Surprise

+0.69%

Boston Scientific Corp.

Report Date

Feb 04, 2026 For Q4 25

Estimate

$0.78

Actual

$0.80

Surprise

+1.61%

ResMed Inc.

Report Date

Jan 29, 2026 For Q2 26

Estimate

$2.75

Actual

$2.81

Surprise

+2.15%

GE HealthCare Technologies Inc. Common Stock

Report Date

Feb 04, 2026 For Q4 25

Estimate

$1.42

Actual

$1.44

Surprise

+0.96%

Envista Holdings Corporation Common stock, $0.01 par value per share

Report Date

Feb 05, 2026 For Q4 25

Estimate

$0.32

Actual

$0.38

Surprise

+15.43%

Prestige Consumer Healthcare Inc.

Report Date

Feb 05, 2026 For Q3 26

Estimate

$1.15

Actual

$1.13

Surprise

-1.36%

Haemonetics Corporation

Report Date

Feb 05, 2026 For Q3 26

Estimate

$1.26

Actual

$1.31

Surprise

+3.75%

Phibro Animal Health Corporation Class A

Report Date

Feb 04, 2026 For Q2 26

Estimate

$0.68

Actual

$0.87

Surprise

+27.30%

Canopy Growth Corporation Common Shares

Report Date

Feb 06, 2026 For Q3 26

Estimate

-$0.04

Actual

-$0.13

Surprise

-198.00%

Aurora Cannabis Inc. Common Shares

Report Date

Feb 04, 2026 For Q3 26

Estimate

$0.21

Actual

$0.12

Surprise

-42.72%

FAQ

What were Nephros Inc.'s earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Nephros Inc. reported EPS of $0.03, beating estimates by 247.06%, and revenue of $4.76M, 20.8% above expectations.

How did the market react to Nephros Inc.'s Q3 2025 earnings?

The stock price moved down -11.54%, changed from $5.20 before the earnings release to $4.60 the day after.

When is Nephros Inc. expected to report next?

The next earning report is scheduled for Mar 05, 2026.

What are the forecasts for Nephros Inc.'s next earnings report?

Based on 4 analysts, Nephros Inc. is expected to report EPS of $0.01 and revenue of $4.54M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.